Great Point Partners LLC Amicus Therapeutics, Inc. Transaction History

Great Point Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$11.43 - $14.24 $2.46 Million - $3.06 Million	215,000 Added 16.79%	1,495,500 $17.6 Million
Q4 2023 Feb 14, 2024	BUY	$9.97 - $14.52 $4.22 Million - $6.15 Million	423,500 Added 49.42%	1,280,500 $18.2 Million
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $1.83 Million - $2.16 Million	155,608 Added 22.19%	857,000 $10.4 Million
Q2 2023 Aug 14, 2023	BUY	$10.72 - $13.3 $3.45 Million - $4.27 Million	321,392 Added 84.58%	701,392 $8.81 Million
Q1 2023 May 15, 2023	BUY	$10.91 - $13.54 $4.15 Million - $5.15 Million	380,000 New	380,000 $4.21 Million
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $2.45 Million - $3.1 Million	-249,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$8.74 - $11.84 $11.8 Million - $16 Million	-1,351,000 Reduced 84.44%	249,000 $2.38 Million
Q2 2021 Aug 16, 2021	BUY	$8.71 - $10.72 $13.9 Million - $17.2 Million	1,600,000 New	1,600,000 $15.4 Million

311

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.53B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.